@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sct: <http://snomed.info/id/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

<http://example.org/br-and-r/soa/Bundle/H2Q-MC-LZZT-Bundle-1> a fhir:Bundle;
  fhir:nodeRole fhir:treeRoot;
  fhir:Resource.id [ fhir:value "H2Q-MC-LZZT-Bundle-1"];
  fhir:Bundle.type [ fhir:value "transaction"];
  fhir:Bundle.entry [
     fhir:index 0;
     fhir:Bundle.entry.resource [
       a fhir:Organization;
       fhir:Resource.id [ fhir:value "EliLillyAndCompany" ];
       fhir:DomainResource.text [
         fhir:Narrative.status [ fhir:value "generated" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><p><b>identifier</b>: id: Eli Lilly and Company (OFFICIAL)</p><p><b>type</b>: <span title=\"Codes: \">crs</span></p></div>"
       ];
       fhir:Organization.identifier [
         fhir:index 0;
         fhir:Identifier.use [ fhir:value "official" ];
         fhir:Identifier.value [ fhir:value "Eli Lilly and Company" ]
       ];
       fhir:Organization.type [
         fhir:index 0;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.code [ fhir:value "crs" ]
         ]
       ]
     ];
     fhir:Bundle.entry.request [
       fhir:Bundle.entry.request.method [ fhir:value "POST" ];
       fhir:Bundle.entry.request.url [ fhir:value "Organization" ]
     ]
  ], [
     fhir:index 1;
     fhir:Bundle.entry.resource [
       a fhir:Practitioner;
       fhir:Resource.id [ fhir:value "SamGetWell" ];
       fhir:DomainResource.text [
         fhir:Narrative.status [ fhir:value "generated" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><p><b>identifier</b>: UPIN: ABC123 (OFFICIAL)</p><p><b>active</b>: true</p><p><b>name</b>: Samuel Home </p><p><b>telecom</b>: ph: 555-123-5467(WORK)</p><p><b>gender</b>: male</p></div>"
       ];
       fhir:Practitioner.identifier [
         fhir:index 0;
         fhir:Identifier.use [ fhir:value "official" ];
         fhir:Identifier.type [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.code [ fhir:value "UPIN" ]
           ]
         ];
         fhir:Identifier.value [ fhir:value "ABC123" ]
       ];
       fhir:Practitioner.active [ fhir:value "true"^^xsd:boolean ];
       fhir:Practitioner.name [
         fhir:index 0;
         fhir:HumanName.use [ fhir:value "usual" ];
         fhir:HumanName.family [ fhir:value "Home" ];
         fhir:HumanName.given [
           fhir:value "Samuel";
           fhir:index 0
         ];
         fhir:HumanName.prefix [
           fhir:value "Dr";
           fhir:index 0
         ];
         fhir:HumanName.suffix [
           fhir:value "M.D.";
           fhir:index 0
         ]
       ];
       fhir:Practitioner.telecom [
         fhir:index 0;
         fhir:ContactPoint.system [ fhir:value "phone" ];
         fhir:ContactPoint.value [ fhir:value "555-123-5467" ];
         fhir:ContactPoint.use [ fhir:value "work" ]
       ];
       fhir:Practitioner.gender [ fhir:value "male" ]
     ];
     fhir:Bundle.entry.request [
       fhir:Bundle.entry.request.method [ fhir:value "POST" ];
       fhir:Bundle.entry.request.url [ fhir:value "Practitioner" ]
     ]
  ], [
     fhir:index 2;
     fhir:Bundle.entry.resource [
       a fhir:PlanDefinition;
       fhir:Resource.id [ fhir:value "LZZT-Study-Definition" ];
       fhir:Resource.meta [
         fhir:Meta.profile [
           fhir:value "http://example.org/br-and-r/soa/StructureDefinition/SOA-study-definition";
           fhir:index 0;
           fhir:link <http://example.org/br-and-r/soa/StructureDefinition/SOA-study-definition>
         ]
       ];
       fhir:DomainResource.text [
         fhir:Narrative.status [ fhir:value "generated" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><p><b>version</b>: 1.0</p><p><b>status</b>: active</p></div>"
       ];
       fhir:PlanDefinition.version [ fhir:value "1.0" ];
       fhir:PlanDefinition.status [ fhir:value "active" ]
     ];
     fhir:Bundle.entry.request [
       fhir:Bundle.entry.request.method [ fhir:value "POST" ];
       fhir:Bundle.entry.request.url [ fhir:value "SOAPlanDefinition" ]
     ]
  ], [
     fhir:index 3;
     fhir:Bundle.entry.resource [
       a fhir:ResearchStudy;
       fhir:Resource.id [ fhir:value "H2Q-MC-LZZT-ResearchStudy" ];
       fhir:DomainResource.text [
         fhir:Narrative.status [ fhir:value "generated" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><p><b>identifier</b>: id: H2Q-MC-LZZT (USUAL), id: NCTA12313212 (OFFICIAL), PLAC: NCTA12313212 (SECONDARY)</p><p><b>title</b>: Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease</p><p><b>protocol</b>: <a href=\"#PlanDefinition_LZZT-Study-Definition\">See above (PlanDefinition/LZZT-Study-Definition)</a></p><p><b>status</b>: completed</p><p><b>primaryPurposeType</b>: <span title=\"Codes: \">treatment</span></p><p><b>phase</b>: <span title=\"Codes: \">phase-3</span></p><p><b>category</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C98388}\">Interventional Study</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C15417}\">Randomized Clinical Trial</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C15228}\">Double Blind Study</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C49648}\">Placebo Control</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C82639}\">Parallel Study</span></p><p><b>focus</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C152926}\">Xanomeline</span>, <span title=\"Codes: {http://ncimeta.nci.nih.gov C149996}\">Transdermal Patch Dosage Form</span></p><p><b>condition</b>: <span title=\"Codes: {http://snomed.info/sct 26929004}\">Alzheimer's Disease (Disorder)</span>, <span title=\"Codes: {http://snomed.info/sct G30}\">Alzheimer's disease</span>, <span title=\"Codes: {http://snomed.info/sct 10001896}\">Alzheimer's disease</span></p><p><b>contact</b>: Bob James, Ph.D.: ph: 555-555-5555(WORK)</p><h3>RelatedArtifacts</h3><table class=\"grid\"><tr><td>-</td></tr><tr><td>*</td></tr></table><p><b>keyword</b>: <span title=\"Codes: {https://id.nlm.nih.gov/mesh D018721}\">Selective M1 muscarinic agonists</span></p><p><b>description</b>: # Xanomeline (LY246708)\n# Protocol H2Q-MC-LZZT(c) \nSafety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease</p><p><b>sponsor</b>: <a href=\"#Organization_EliLillyAndCompany\">See above (Organization/EliLillyAndCompany)</a></p><p><b>principalInvestigator</b>: <a href=\"#Practitioner_SamGetWell\">See above (Practitioner/SamGetWell)</a></p><blockquote><p><b>arm</b></p><p><b>name</b>: Placebo</p><p><b>type</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C49648}\">C49648</span></p><p><b>description</b>: Placebo arm</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: Low-dose xanomeline arm</p><p><b>type</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C174266}\">C174266</span></p><p><b>description</b>: Low-dose xanomeline arm (50 cm2 TTS Formulation E, 54 mg xanomeline)</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: High-dose xanomeline arm</p><p><b>type</b>: <span title=\"Codes: {http://ncimeta.nci.nih.gov C174266}\">C174266</span></p><p><b>description</b>: High-dose xanomeline arm (75 cm2 TTS Formulation E, 81 mg xanomeline)</p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To determine if there is a statistically significant relationship (overall Type 1 error rate, α=.05) between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).</p><p><b>type</b>: <span title=\"Codes: \">primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To document the safety profile of the xanomeline TTS.</p><p><b>type</b>: <span title=\"Codes: \">primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer’s Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the treatment response as a function of Apo E genotype.</p><p><b>type</b>: <span title=\"Codes: \">secondary</span></p></blockquote></div>"
       ];
       fhir:ResearchStudy.identifier [
         fhir:index 0;
         fhir:Identifier.use [ fhir:value "usual" ];
         fhir:Identifier.value [ fhir:value "H2Q-MC-LZZT" ]
       ], [
         fhir:index 1;
         fhir:Identifier.use [ fhir:value "official" ];
         fhir:Identifier.system [ fhir:value "https://clinicaltrials.gov/show/" ];
         fhir:Identifier.value [ fhir:value "NCTA12313212" ]
       ], [
         fhir:index 2;
         fhir:Identifier.use [ fhir:value "secondary" ];
         fhir:Identifier.type [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.code [ fhir:value "PLAC" ]
           ]
         ];
         fhir:Identifier.value [ fhir:value "NCTA12313212" ]
       ];
       fhir:ResearchStudy.title [ fhir:value "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease" ];
       fhir:ResearchStudy.protocol [
         fhir:index 0;
         fhir:link <http://example.org/br-and-r/soa/PlanDefinition/LZZT-Study-Definition>;
         fhir:Reference.reference [ fhir:value "PlanDefinition/LZZT-Study-Definition" ]
       ];
       fhir:ResearchStudy.status [ fhir:value "completed" ];
       fhir:ResearchStudy.primaryPurposeType [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.code [ fhir:value "treatment" ]
         ]
       ];
       fhir:ResearchStudy.phase [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.code [ fhir:value "phase-3" ]
         ]
       ];
       fhir:ResearchStudy.category [
         fhir:index 0;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://ncimeta.nci.nih.gov" ];
           fhir:Coding.code [ fhir:value "C98388" ];
           fhir:Coding.display [ fhir:value "Interventional Study" ]
         ]
       ], [
         fhir:index 1;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://ncimeta.nci.nih.gov" ];
           fhir:Coding.code [ fhir:value "C15417" ];
           fhir:Coding.display [ fhir:value "Randomized Clinical Trial" ]
         ]
       ], [
         fhir:index 2;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://ncimeta.nci.nih.gov" ];
           fhir:Coding.code [ fhir:value "C15228" ];
           fhir:Coding.display [ fhir:value "Double Blind Study" ]
         ]
       ], [
         fhir:index 3;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://ncimeta.nci.nih.gov" ];
           fhir:Coding.code [ fhir:value "C49648" ];
           fhir:Coding.display [ fhir:value "Placebo Control" ]
         ]
       ], [
         fhir:index 4;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://ncimeta.nci.nih.gov" ];
           fhir:Coding.code [ fhir:value "C82639" ];
           fhir:Coding.display [ fhir:value "Parallel Study" ]
         ]
       ];
       fhir:ResearchStudy.focus [
         fhir:index 0;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://ncimeta.nci.nih.gov" ];
           fhir:Coding.code [ fhir:value "C152926" ];
           fhir:Coding.display [ fhir:value "Xanomeline" ]
         ]
       ], [
         fhir:index 1;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://ncimeta.nci.nih.gov" ];
           fhir:Coding.code [ fhir:value "C149996" ];
           fhir:Coding.display [ fhir:value "Transdermal Patch Dosage Form" ]
         ]
       ];
       fhir:ResearchStudy.condition [
         fhir:index 0;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           a sct:26929004;
           fhir:Coding.system [ fhir:value "http://snomed.info/sct" ];
           fhir:Coding.code [ fhir:value "26929004" ];
           fhir:Coding.display [ fhir:value "Alzheimer's Disease (Disorder)" ]
         ]
       ], [
         fhir:index 1;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           a sct:G30;
           fhir:Coding.system [ fhir:value "http://snomed.info/sct" ];
           fhir:Coding.code [ fhir:value "G30" ];
           fhir:Coding.display [ fhir:value "Alzheimer's disease" ]
         ]
       ], [
         fhir:index 2;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           a sct:10001896;
           fhir:Coding.system [ fhir:value "http://snomed.info/sct" ];
           fhir:Coding.code [ fhir:value "10001896" ];
           fhir:Coding.display [ fhir:value "Alzheimer's disease" ]
         ]
       ];
       fhir:ResearchStudy.contact [
         fhir:index 0;
         fhir:ContactDetail.name [ fhir:value "Bob James, Ph.D." ];
         fhir:ContactDetail.telecom [
           fhir:index 0;
           fhir:ContactPoint.system [ fhir:value "phone" ];
           fhir:ContactPoint.value [ fhir:value "555-555-5555" ];
           fhir:ContactPoint.use [ fhir:value "work" ]
         ]
       ];
       fhir:ResearchStudy.relatedArtifact [
         fhir:index 0;
         fhir:RelatedArtifact.type [ fhir:value "documentation" ];
         fhir:RelatedArtifact.label [ fhir:value "Protocol H2Q-MC-LZZT(c)" ];
         fhir:RelatedArtifact.url [ fhir:value "https://clinicaltrials.gov/show/NCTA12313212/Lzzt_protocol_redacted.pdf" ]
       ];
       fhir:ResearchStudy.keyword [
         fhir:index 0;
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "https://id.nlm.nih.gov/mesh" ];
           fhir:Coding.code [ fhir:value "D018721" ]
         ];
         fhir:CodeableConcept.text [ fhir:value "Selective M1 muscarinic agonists" ]
       ];
       fhir:ResearchStudy.description [ fhir:value "# Xanomeline (LY246708)\n# Protocol H2Q-MC-LZZT(c) \nSafety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease" ];
       fhir:ResearchStudy.sponsor [
         fhir:link <http://example.org/br-and-r/soa/Organization/EliLillyAndCompany>;
         fhir:Reference.reference [ fhir:value "Organization/EliLillyAndCompany" ]
       ];
       fhir:ResearchStudy.principalInvestigator [
         fhir:link <http://example.org/br-and-r/soa/Practitioner/SamGetWell>;
         fhir:Reference.reference [ fhir:value "Practitioner/SamGetWell" ]
       ];
       fhir:ResearchStudy.arm [
         fhir:index 0;
         fhir:ResearchStudy.arm.name [ fhir:value "Placebo" ];
         fhir:ResearchStudy.arm.type [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://ncimeta.nci.nih.gov" ];
             fhir:Coding.code [ fhir:value "C49648" ]
           ]
         ];
         fhir:ResearchStudy.arm.description [ fhir:value "Placebo arm" ]
       ], [
         fhir:index 1;
         fhir:ResearchStudy.arm.name [ fhir:value "Low-dose xanomeline arm" ];
         fhir:ResearchStudy.arm.type [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://ncimeta.nci.nih.gov" ];
             fhir:Coding.code [ fhir:value "C174266" ]
           ]
         ];
         fhir:ResearchStudy.arm.description [ fhir:value "Low-dose xanomeline arm (50 cm2 TTS Formulation E, 54 mg xanomeline)" ]
       ], [
         fhir:index 2;
         fhir:ResearchStudy.arm.name [ fhir:value "High-dose xanomeline arm" ];
         fhir:ResearchStudy.arm.type [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://ncimeta.nci.nih.gov" ];
             fhir:Coding.code [ fhir:value "C174266" ]
           ]
         ];
         fhir:ResearchStudy.arm.description [ fhir:value "High-dose xanomeline arm (75 cm2 TTS Formulation E, 81 mg xanomeline)" ]
       ];
       fhir:ResearchStudy.objective [
         fhir:index 0;
         fhir:ResearchStudy.objective.name [ fhir:value "To determine if there is a statistically significant relationship (overall Type 1 error rate, α=.05) between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])." ];
         fhir:ResearchStudy.objective.type [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.code [ fhir:value "primary" ]
           ]
         ]
       ], [
         fhir:index 1;
         fhir:ResearchStudy.objective.name [ fhir:value "To document the safety profile of the xanomeline TTS." ];
         fhir:ResearchStudy.objective.type [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.code [ fhir:value "primary" ]
           ]
         ]
       ], [
         fhir:index 2;
         fhir:ResearchStudy.objective.name [ fhir:value "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas." ];
         fhir:ResearchStudy.objective.type [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.code [ fhir:value "secondary" ]
           ]
         ]
       ], [
         fhir:index 3;
         fhir:ResearchStudy.objective.name [ fhir:value "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas." ];
         fhir:ResearchStudy.objective.type [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.code [ fhir:value "secondary" ]
           ]
         ]
       ], [
         fhir:index 4;
         fhir:ResearchStudy.objective.name [ fhir:value "To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer’s Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment." ];
         fhir:ResearchStudy.objective.type [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.code [ fhir:value "secondary" ]
           ]
         ]
       ], [
         fhir:index 5;
         fhir:ResearchStudy.objective.name [ fhir:value "To assess the treatment response as a function of Apo E genotype." ];
         fhir:ResearchStudy.objective.type [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.code [ fhir:value "secondary" ]
           ]
         ]
       ]
     ];
     fhir:Bundle.entry.request [
       fhir:Bundle.entry.request.method [ fhir:value "POST" ];
       fhir:Bundle.entry.request.url [ fhir:value "ResearchStudy" ]
     ]
  ] .

# - ontology header ------------------------------------------------------------

<http://example.org/br-and-r/soa/Bundle/H2Q-MC-LZZT-Bundle-1.ttl> a owl:Ontology;
  owl:imports fhir:fhir.ttl .

# -------------------------------------------------------------------------------------

